INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 231 filers reported holding INOVIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,438 | +573.9% | 55,110 | +674.2% | 0.00% | – |
| Q2 2023 | $3,181 | -99.5% | 7,118 | -99.1% | 0.00% | – |
| Q1 2023 | $655,273 | -54.2% | 799,112 | -12.8% | 0.00% | -100.0% |
| Q4 2022 | $1,429,959 | +173.9% | 916,640 | +202.9% | 0.00% | – |
| Q3 2022 | $522,000 | -50.1% | 302,627 | -49.9% | 0.00% | – |
| Q2 2022 | $1,046,000 | -82.2% | 604,245 | -63.2% | 0.00% | -100.0% |
| Q1 2022 | $5,888,000 | +43.4% | 1,640,012 | +99.3% | 0.00% | +100.0% |
| Q4 2021 | $4,105,000 | +25.4% | 822,715 | +80.0% | 0.00% | 0.0% |
| Q3 2021 | $3,273,000 | +266.9% | 457,138 | +374.7% | 0.00% | – |
| Q2 2021 | $892,000 | -11.1% | 96,294 | -10.9% | 0.00% | – |
| Q1 2021 | $1,003,000 | +97.8% | 108,041 | +88.5% | 0.00% | – |
| Q4 2020 | $507,000 | -19.3% | 57,315 | +5.9% | 0.00% | – |
| Q3 2020 | $628,000 | -54.2% | 54,142 | +6.5% | 0.00% | -100.0% |
| Q2 2020 | $1,370,000 | +456.9% | 50,823 | +53.3% | 0.00% | – |
| Q1 2020 | $246,000 | -41.3% | 33,150 | -73.9% | 0.00% | – |
| Q4 2019 | $419,000 | +177.5% | 126,782 | +72.5% | 0.00% | – |
| Q3 2019 | $151,000 | +202.0% | 73,499 | +331.1% | 0.00% | – |
| Q2 2019 | $50,000 | -95.2% | 17,050 | -93.9% | 0.00% | – |
| Q1 2019 | $1,044,000 | -48.7% | 279,762 | -45.1% | 0.00% | -100.0% |
| Q4 2018 | $2,037,000 | +34.1% | 509,241 | +86.3% | 0.00% | 0.0% |
| Q3 2018 | $1,519,000 | +34.9% | 273,276 | -4.9% | 0.00% | – |
| Q2 2018 | $1,126,000 | -46.0% | 287,360 | -35.1% | 0.00% | -100.0% |
| Q1 2018 | $2,086,000 | +192.6% | 442,893 | +156.7% | 0.00% | – |
| Q4 2017 | $713,000 | -62.7% | 172,520 | -42.8% | 0.00% | -100.0% |
| Q3 2017 | $1,911,000 | +35.8% | 301,492 | +68.0% | 0.00% | 0.0% |
| Q2 2017 | $1,407,000 | +31.6% | 179,410 | +11.2% | 0.00% | 0.0% |
| Q1 2017 | $1,069,000 | -40.7% | 161,410 | -37.9% | 0.00% | 0.0% |
| Q4 2016 | $1,803,000 | -3.8% | 259,758 | +29.1% | 0.00% | 0.0% |
| Q3 2016 | $1,875,000 | +0.6% | 201,205 | -0.2% | 0.00% | 0.0% |
| Q2 2016 | $1,863,000 | +61.0% | 201,511 | +51.7% | 0.00% | 0.0% |
| Q1 2016 | $1,157,000 | +12.8% | 132,850 | -13.0% | 0.00% | 0.0% |
| Q4 2015 | $1,026,000 | +24.4% | 152,743 | +7.0% | 0.00% | 0.0% |
| Q3 2015 | $825,000 | -19.5% | 142,700 | +13.6% | 0.00% | 0.0% |
| Q2 2015 | $1,025,000 | +8.9% | 125,650 | +9.0% | 0.00% | 0.0% |
| Q1 2015 | $941,000 | -39.3% | 115,300 | -31.7% | 0.00% | 0.0% |
| Q4 2014 | $1,550,000 | – | 168,813 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |